{"DataElement":{"publicId":"6180795","version":"1","preferredName":"Oropharyngeal p16-Negative Cancer AJCC Edition 8 Pathologic Regional Lymph Node N Category","preferredDefinition":"Extent of the distant metastasis for p16-negative oropharyngeal carcinoma based on information obtained from the date of cancer diagnosis until the start of definitive treatment, or within four months (whichever is shorter), using AJCC Ed.","longName":"OX16N_AJC8_PTH_N_CAT","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6052659","version":"1","preferredName":"Oropharynx Neoplasm CDKN2A-p16 Negative Pathologic N Category","preferredDefinition":"The part of the pharynx between the soft palate and the upper portion of the epiglottis._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._Indicates that expression of the p16 form of CDKN2A has not been detected in a sample._Caused by or altered by or manifesting disease or pathology._One criteria of the TNM staging system. N refers to the extent of lymph node involvement.","longName":"6052651v1.0:6072199v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6052651","version":"1","preferredName":"Oropharynx Neoplasm","preferredDefinition":"The part of the pharynx between the soft palate and the upper portion of the epiglottis.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"C12762:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharynx","conceptCode":"C12762","definition":"The part of the pharynx between the soft palate and the upper portion of the epiglottis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630C1054-6248-5BD4-E053-F662850A4B08","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6072199","version":"1","preferredName":"CDKN2A-p16 Negative Pathologic N Stage","preferredDefinition":"Indicates that expression of the p16 form of CDKN2A has not been detected in a sample.:Caused by or altered by or manifesting disease or pathology.:One criteria of the TNM staging system.  N refers to the extent of lymph node involvement.","longName":"C132226:C25610:C25580","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CDKN2A-p16 Negative","conceptCode":"C132226","definition":"Indicates that expression of the p16 form of CDKN2A has not been detected in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"N Category","conceptCode":"C25580","definition":"One criteria of the TNM staging system. N refers to the extent of lymph node involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"653660B5-3205-7A28-E053-F662850A6761","latestVersionIndicator":"Yes","beginDate":"2018-02-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-15","modifiedBy":"ONEDATA","dateModified":"2018-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"630C2564-13AA-5DC2-E053-F662850AE62E","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"TAYLORT","dateModified":"2018-04-09","changeDescription":"4/9/18 tt released. 1/18/18 tt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6052723","version":"1","preferredName":"Oropharyngeal (p16-Negative) Carcinoma American Joint Committee on Cancer Edition 8 Pathologic N Category","preferredDefinition":"A pathologic finding about one or more characteristics of oropharyngeal (p16-negative) cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes._A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._One criteria of the TNM staging system.  N refers to the extent of lymph node involvement._A grouping of items based on some commonality or by user defined characteristics.","longName":"6052723v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"N3b","valueDescription":"Oropharyngeal (p16-Negative) Cancer pN3b TNM Finding v8","ValueMeaning":{"publicId":"6052727","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer pN3b TNM Finding v8","longName":"6052727","preferredDefinition":"Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer pN3b TNM Finding v8","conceptCode":"C132977","definition":"Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630E854F-01A1-7EA9-E053-F662850A6728","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630E854F-01BA-7EA9-E053-F662850A6728","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"N3a","valueDescription":"Oropharyngeal (p16-Negative) Cancer pN3a TNM Finding v8","ValueMeaning":{"publicId":"6052729","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer pN3a TNM Finding v8","longName":"6052729","preferredDefinition":"Oropharyngeal (p16-negative) cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer pN3a TNM Finding v8","conceptCode":"C132975","definition":"Oropharyngeal (p16-negative) cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630E854F-01C7-7EA9-E053-F662850A6728","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630E854F-01E0-7EA9-E053-F662850A6728","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"N3","valueDescription":"Oropharyngeal (p16-Negative) Cancer pN3 TNM Finding v8","ValueMeaning":{"publicId":"6052731","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer pN3 TNM Finding v8","longName":"6052731","preferredDefinition":"Oropharyngeal (p16-negative) cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer pN3 TNM Finding v8","conceptCode":"C132973","definition":"Oropharyngeal (p16-negative) cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630E854F-01ED-7EA9-E053-F662850A6728","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630E854F-0206-7EA9-E053-F662850A6728","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"N2c","valueDescription":"Oropharyngeal (p16-Negative) Cancer pN2c TNM Finding v8","ValueMeaning":{"publicId":"6052733","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer pN2c TNM Finding v8","longName":"6052733","preferredDefinition":"Oropharyngeal (p16-negative) cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer pN2c TNM Finding v8","conceptCode":"C132971","definition":"Oropharyngeal (p16-negative) cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630E854F-0213-7EA9-E053-F662850A6728","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630E854F-022C-7EA9-E053-F662850A6728","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"N2b","valueDescription":"Oropharyngeal (p16-Negative) Cancer pN2b TNM Finding v8","ValueMeaning":{"publicId":"6052735","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer pN2b TNM Finding v8","longName":"6052735","preferredDefinition":"Oropharyngeal (p16-negative) cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer pN2b TNM Finding v8","conceptCode":"C132969","definition":"Oropharyngeal (p16-negative) cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630E854F-0239-7EA9-E053-F662850A6728","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630E854F-0252-7EA9-E053-F662850A6728","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"N2a","valueDescription":"Oropharyngeal (p16-Negative) Cancer pN2a TNM Finding v8","ValueMeaning":{"publicId":"6052737","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer pN2a TNM Finding v8","longName":"6052737","preferredDefinition":"Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer pN2a TNM Finding v8","conceptCode":"C132966","definition":"Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630E854F-025F-7EA9-E053-F662850A6728","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630E854F-0278-7EA9-E053-F662850A6728","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"N2","valueDescription":"Oropharyngeal (p16-Negative) Cancer pN2 TNM Finding v8","ValueMeaning":{"publicId":"6052739","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer pN2 TNM Finding v8","longName":"6052739","preferredDefinition":"Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer pN2 TNM Finding v8","conceptCode":"C132965","definition":"Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630E854F-0285-7EA9-E053-F662850A6728","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630E854F-029E-7EA9-E053-F662850A6728","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"N1","valueDescription":"Oropharyngeal (p16-Negative) Cancer pN1 TNM Finding v8","ValueMeaning":{"publicId":"6052741","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer pN1 TNM Finding v8","longName":"6052741","preferredDefinition":"Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer pN1 TNM Finding v8","conceptCode":"C132963","definition":"Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630E854F-02AB-7EA9-E053-F662850A6728","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630E854F-02C4-7EA9-E053-F662850A6728","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"N0","valueDescription":"Oropharyngeal (p16-Negative) Cancer pN0 TNM Finding v8","ValueMeaning":{"publicId":"6052743","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer pN0 TNM Finding v8","longName":"6052743","preferredDefinition":"Oropharyngeal (p16-negative) cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer pN0 TNM Finding v8","conceptCode":"C132961","definition":"Oropharyngeal (p16-negative) cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630E854F-02D1-7EA9-E053-F662850A6728","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630E854F-02EA-7EA9-E053-F662850A6728","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"NX","valueDescription":"Oropharyngeal (p16-Negative) Cancer pNX TNM Finding v8","ValueMeaning":{"publicId":"6052725","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer pNX TNM Finding v8","longName":"6052725","preferredDefinition":"Oropharyngeal (p16-negative) cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer pNX TNM Finding v8","conceptCode":"C132959","definition":"Oropharyngeal (p16-negative) cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630E854F-017B-7EA9-E053-F662850A6728","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"63ED0363-AA1F-2364-E053-F662850AC6B9","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-29","modifiedBy":"ONEDATA","dateModified":"2018-01-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6052722","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer Pathologic Regional Lymph Nodes TNM Finding v8 American Joint Committee on Cancer N Category Category","preferredDefinition":"A pathologic finding about one or more characteristics of oropharyngeal (p16-negative) cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.:A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:One criteria of the TNM staging system.  N refers to the extent of lymph node involvement.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C132937:C39315:C25580:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer Pathologic Regional Lymph Nodes TNM Finding v8","conceptCode":"C132937","definition":"A pathologic finding about one or more characteristics of oropharyngeal (p16-negative) cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"N Category","conceptCode":"C25580","definition":"One criteria of the TNM staging system. N refers to the extent of lymph node involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630E854F-014E-7EA9-E053-F662850A6728","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"630E854F-015F-7EA9-E053-F662850A6728","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"TAYLORT","dateModified":"2018-04-09","changeDescription":"4/9/18 tt released. 1/18/18 tt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3896529","version":"1","longName":"Consortia 2012 Studies","context":"DCP","ClassificationSchemeItems":[{"publicId":"5280817","version":"1","longName":"UWI2016-07-01","context":"DCP"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"6052641","version":"1","longName":"Oropharyngeal","context":"NCI Standards"}]}],"AlternateNames":[{"name":"DCP","type":"USED_BY","context":"DCP"}],"ReferenceDocuments":[{"name":"Pathologic N category","type":"Preferred Question Text","description":"Pathologic N category","url":null,"context":"NCI Standards"},{"name":"DCP Text-1","type":"Alternate Question Text","description":"p16-: Node Stage (V8)","url":null,"context":"DCP"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"696B33D1-48DB-2B52-E053-F662850A1677","latestVersionIndicator":"Yes","beginDate":"2018-04-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-09","modifiedBy":"KNABLEJ","dateModified":"2020-01-14","changeDescription":"4/9/18 tt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}